Cargando…
Isatuximab: A Review of Its Use in Multiple Myeloma
Isatuximab (Sarclisa(®); isatuximab-irfc in the USA) is an anti-CD38 monoclonal antibody (mAb) approved for use in the treatment of adults with multiple myeloma (MM): in combination with pomalidomide and dexamethasone for those with relapsed and refractory MM (RRMM) who have received ≥ 2 prior thera...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497289/ https://www.ncbi.nlm.nih.gov/pubmed/34351561 http://dx.doi.org/10.1007/s11523-021-00827-0 |